Terms: = Skin cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
5 results:
1. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.
Zhou M; Zhu S; Xu C; Liu B; Shen J
Invest New Drugs; 2023 Feb; 41(1):162-167. PubMed ID: 36763233
[TBL] [Abstract] [Full Text] [Related]
2. Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis.
Pathmanathan S; Babu H; Dzienis M; Azer M; Eastgate M
Pigment Cell Melanoma Res; 2022 Nov; 35(6):587-594. PubMed ID: 36065524
[TBL] [Abstract] [Full Text] [Related]
3. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Smalley KS; Flaherty KT
Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
[TBL] [Abstract] [Full Text] [Related]
4. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
Meijer D; Sieuwerts AM; Look MP; van Agthoven T; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2008 Mar; 15(1):101-11. PubMed ID: 18310279
[TBL] [Abstract] [Full Text] [Related]
5. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.
Regazzoni S; Pesce G; Marini G; Cavalli F; Goldhirsch A
Ann Oncol; 1996 Oct; 7(8):807-13. PubMed ID: 8922194
[TBL] [Abstract] [Full Text] [Related]
